MSB

7.69%

$1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-425

First 425 Last

Share
Profile

Follow
IndexInvestor

8,407 Posts.

1383

05/10/20

20:08

Post #: 47865284
Share

Originally posted by bedger: ↑

Kervio, an excellent post as ever and pause for thought for even the most optimistic on here. Given you excellent objective reasoning (that is hard to contest) I would be curious to your opinion on two things that come to mind for me from your post.

A: If ultimately the main reasoning for voting against MSB was conservative thinking and self-protection, why have we seen other decisions, many cited examples in this thread, where the FDA has over-ruled a conservative and disapproving ODAC decision to grant approval to other less rigourously tested treatments, even with suspected safety issues? Would you put it down to sheer inconsistency across decisions or some other reasoning? Why 'protect their asses' here when they exposed them on others?

B: Whilst ultimately the GvHD FDA RCT stance would indeed push MSB to wanting full and uncontestable results for ARDS trials, are they not simply by the Bayesian and independent assessment design, ransomed to the results as they fall? That is, by deisgn (per FDA and MSB) are not both MSB and the FDA subject to pushing REM-L for emergencey use by the decision of the DMCB which will be solely based on the stats?

I made the mistake of being so impressed by the presentations of MSB in the ODAC meeting (in answering the FDA's concerns) and looking at precedence in ODAC advisories, that I never thought FDA would not approve. But I am not well experienced in these matters. The MSB Board are. I am going to be unpopular, but given it appears the FDA could never demand a conditional trail under the BLA application and MSB knew the FDA would likely require an RCT (and indeed planned for one), was it perhaps an oversight for MSB to have gone down this route in the first place? Should they have not gone down the accelerated path in the first place?

Expand

May I interject and answer the questions addressed to Kervio?

A. IMO because the historical decisions were about drugs, but this is about a biologic and the first of its type.

B. Yes. But if the DSMB finds overwhelming efficacy at an interim review, MSB can still decide to continue the treatment arm on the full 150 patients, and even switch the remaining placebo patients onto the treatment.

MSB Price at posting: $3.56 Sentiment: Hold Disclosure: Held
7 Upvote

1 Great analysis

Reply

Top Stories

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

There are more pages in this discussion • 593 more messages in this thread...

First 425 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.19		Change 0.085(7.69%)		Mkt cap ! $1.358B

Open	High	Low	Value	Volume
$1.10	$1.20	$1.09	$13.21M	11.37M

Buyers (Bids)

No.	Vol.	Price($)
1	15000	$1.19

Sellers (Offers)

Price($)	Vol.	No.
$1.19	75212	5

View Market Depth

No.	Vol.	Price($)
1	15000	1.185
1	20000	1.175
1	5664	1.170
1	17568	1.160
3	56695	1.150

Price($)	Vol.	No.
1.190	59712	2
1.195	36255	5
1.200	404381	31
1.205	3000	1
1.210	162475	7

Last trade - 16.10pm 12/07/2024 (20 minute delay)

MSB (ASX) Chart

MSB to dispute FDA finding in Type A meeting, page-425

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Immutep reports strong response rate from immunotherapies treating carcinomas

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB to dispute FDA finding in Type A meeting, page-425

Top Stories

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Immutep reports strong response rate from immunotherapies treating carcinomas

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nimy to raise $1.21M to explore 'newsy' WA targets

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Bitcoin investors need to know the risks

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News